大葉大學圖書館 |

Cancer immunotherapy[electronic resource] :immune suppression and tumor growth /

レコード種別:	言語・文字資料 (印刷物) : 単行資料
[NT 15000414] null:	616.99/4061
タイトル / 著者:	Cancer immunotherapy : immune suppression and tumor growth // edited by George Prendergast, Elizabeth M. Jaffee.
その他の著者:	Prendergast, George C.
出版された:	Amsterdam ; : Academic Press/Elsevier,, c2007.
記述:	xiii, 409 p., [4] p. of plates : : ill. (some col.) ;; 27 cm.
主題:	Cancer - Immunotherapy.
主題:	Antineoplastic agents - Therapeutic use.
主題:	Tumors - Immunological aspects.
主題:	Neoplasms - therapy.
主題:	Antineoplastic Agents - therapeutic use.
主題:	Immunotherapy - methods.
国際標準図書番号 (ISBN) :	9780123725516
国際標準図書番号 (ISBN) :	0123725518
[NT 15000227] null:	Includes bibliographical references and index.
[NT 15000228] null:	Part I: Principles of Cancer Immunobiology -- Introduction -- Cancer Immunoediting: From Immune Surveillance to Immune Escape -- Immunosurveillance: Innate and Adaptive Anti-Tumor Immunity -- Cytokine Regulation of Immune Tolerance to Tumors -- Immunological Sculpting: Natural Killer Cell Receptors and Ligands -- Immune Escape: Immunosuppressive Networks -- Part II: Cancer Therapeutics -- Cytotoxic Chemotherapy in Clinical Treatment of Cancer -- Targeted Therapeutics in Cancer Treatment -- Concepts in Pharmacology and Toxicology -- Cancer Immunotherapy: Challenges and Opportunities -- Cancer Vaccines -- Part III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune Suppression -- Immunotherapy and Cancer Therapeutics: Why Partner? -- Immune Stimulatory Features of Classical Chemotherapy -- Dendritic Cells and Co-Inhibitory Molecules -- Regulatory T Cells in Tumor Immunity: Role of Toll-like Receptors -- Tumor-associated Macrophages in Cancer Growth and Progression -- Tumor-associated Myeloid-derived Suppressor Cells -- Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune Escape -- IDO in Immune Escape: Regulation and Therapeutic Inhibition -- Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation -- Summary: Future Questions.
[NT 15000229] null:	There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. * Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication * Drs Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research * Summarizes the latest insights into how immune escape defines an essential trait of cancer * Includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression.
電子資源:	An electronic book accessible through the World Wide Web; click for information
電子資源:	An electronic book accessible through the World Wide Web; click for information
電子資源:	http://www.loc.gov/catdir/toc/ecip0716/2007016864.html
電子資源:	http://www.loc.gov/catdir/enhancements/fy0733/2007016864-d.html

Cancer immunotherapy[electronic resource] :immune suppression and tumor growth /
Cancer immunotherapyimmune suppression and tumor growth /[electronic resource] :edited by George Prendergast, Elizabeth M. Jaffee. - Amsterdam ;Academic Press/Elsevier,c2007. - xiii, 409 p., [4] p. of plates :ill. (some col.) ;27 cm.

Includes bibliographical references and index.

Part I: Principles of Cancer Immunobiology -- Introduction -- Cancer Immunoediting: From Immune Surveillance to Immune Escape -- Immunosurveillance: Innate and Adaptive Anti-Tumor Immunity -- Cytokine Regulation of Immune Tolerance to Tumors -- Immunological Sculpting: Natural Killer Cell Receptors and Ligands -- Immune Escape: Immunosuppressive Networks -- Part II: Cancer Therapeutics -- Cytotoxic Chemotherapy in Clinical Treatment of Cancer -- Targeted Therapeutics in Cancer Treatment -- Concepts in Pharmacology and Toxicology -- Cancer Immunotherapy: Challenges and Opportunities -- Cancer Vaccines -- Part III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune Suppression -- Immunotherapy and Cancer Therapeutics: Why Partner? -- Immune Stimulatory Features of Classical Chemotherapy -- Dendritic Cells and Co-Inhibitory Molecules -- Regulatory T Cells in Tumor Immunity: Role of Toll-like Receptors -- Tumor-associated Macrophages in Cancer Growth and Progression -- Tumor-associated Myeloid-derived Suppressor Cells -- Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune Escape -- IDO in Immune Escape: Regulation and Therapeutic Inhibition -- Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation -- Summary: Future Questions.

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. * Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication * Drs Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research * Summarizes the latest insights into how immune escape defines an essential trait of cancer * Includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression.

Electronic reproduction.
Amsterdam :
Elsevier Science & Technology,
2007.

Mode of access: World Wide Web.

ISBN: 9780123725516

Source: 133760:133886Elsevier Science & Technologyhttp://www.sciencedirect.comSubjects--Topical Terms:

406740
Cancer
--Immunotherapy.Index Terms--Genre/Form:

336502
Electronic books.

LC Class. No.: RC271.I45 / C363 2007eb

Dewey Class. No.: 616.99/4061

National Library of Medicine Call No.: 2007 H-238

Cancer immunotherapy[electronic resource] :immune suppression and tumor growth /
LDR:07034nam 2200409Ia 4500 001 341481
003 OCoLC
005 20090612093507.0
006 m d
007 cr cn|||||||||
008 110627s2007 ne af sb 001 0 eng d
020 $a 9780123725516
020 $a 0123725518
029 1 $a NZ1 $b 11778500
035 $a (OCoLC)162574047
035 $a ocn162574047
037 $a 133760:133886 $b Elsevier Science & Technology $n http://www.sciencedirect.com
040 $a OPELS $c OPELS
049 $a TEFA
050 1 4 $a RC271.I45 $b C363 2007eb
060 1 4 $a 2007 H-238
060 1 4 $a QZ 266 $b C2146 2007
082 0 4 $a 616.99/4061 $2 22
245 0 0 $a Cancer immunotherapy $h [electronic resource] : $b immune suppression and tumor growth / $c edited by George Prendergast, Elizabeth M. Jaffee.
260 $a Amsterdam ; $a Boston : $b Academic Press/Elsevier, $c c2007.
300 $a xiii, 409 p., [4] p. of plates : $b ill. (some col.) ; $c 27 cm.
504 $a Includes bibliographical references and index.
505 0 $a Part I: Principles of Cancer Immunobiology -- Introduction -- Cancer Immunoediting: From Immune Surveillance to Immune Escape -- Immunosurveillance: Innate and Adaptive Anti-Tumor Immunity -- Cytokine Regulation of Immune Tolerance to Tumors -- Immunological Sculpting: Natural Killer Cell Receptors and Ligands -- Immune Escape: Immunosuppressive Networks -- Part II: Cancer Therapeutics -- Cytotoxic Chemotherapy in Clinical Treatment of Cancer -- Targeted Therapeutics in Cancer Treatment -- Concepts in Pharmacology and Toxicology -- Cancer Immunotherapy: Challenges and Opportunities -- Cancer Vaccines -- Part III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune Suppression -- Immunotherapy and Cancer Therapeutics: Why Partner? -- Immune Stimulatory Features of Classical Chemotherapy -- Dendritic Cells and Co-Inhibitory Molecules -- Regulatory T Cells in Tumor Immunity: Role of Toll-like Receptors -- Tumor-associated Macrophages in Cancer Growth and Progression -- Tumor-associated Myeloid-derived Suppressor Cells -- Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune Escape -- IDO in Immune Escape: Regulation and Therapeutic Inhibition -- Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation -- Summary: Future Questions.
505 0 $a Introduction / George C. Prendergast and Elizabeth M. Jaffee -- Cancer immunoediting : from immune surveillance to immune escape / Ryungsa Kim -- Immunosurveillance : innate and adaptive antitumor immunity / Masahisa Jinushi and Glenn Dranoff -- Cytokine regulation of immune tolerance to tumors / Ming O. Li and Richard A. Flavell -- Immunological sculpting : natural killer cell receptors and ligands / David A. Sallman and Julie Y. Djeu -- Immune escape : immunosuppressive networks / Shuang Wei, Alfred Chang, and Weiping Zou -- Cytotoxic chemotherapy in clinical treatment of cancer / Rajesh Thirumaran, George C. Prendergast, and Paul B. Gilman -- Targeted therapeutics in cancer treatment / Colin D. Weekes and Manuel Hidalgo -- Concepts in pharmacology and toxicology / Richard A. Westhouse and Bruce D. Car -- Cancer immunotherapy : challenges and opportunities / Andrew J. Lepisto, John R. McKolanis, and Olivera J. Finn -- Cancer vaccines / Freda K. Stevenson ... [et al.] --
505 0 $a Immunotherapy and cancer therapeutics : why partner? / Leisha A. Emens and Elizabeth M. Jaffee -- Immune stimulatory features of classical chemotherapy / Robbert G. van der Most, Anna K. Nowak, and Richard A. Lake -- Dendritic cells and coregulatory signals : immune checkpoint blockade to stimulate immunotherapy / Drew Pardoll -- Regulatory T cells in tumor immunity : role of toll-like receptors / Rong-Fu Wang -- Tumor-associated macrophages in cancer growth and progression / Alberto Mantovani, Paola Allavena, and Antonio Sica -- Tumor-associated myeloid-derived suppressor cells / Stephanie K. Bunt ... [et al.] -- Programmed death ligand-1 and galectin-1 : pieces in the puzzle of tumor-immune escape / Gabriel A. Rabinovich and Thomas F. Gajewski -- Indoleamine 2,3-dioxygenase in immune escape : regulation and therapeutic inhibition / Alexander J. Muller and George C. Prendergast -- Arginase, nitric oxide synthase, and novel inhibitors of L-arginine metabolism in immune modulation / Susanna Mandruzzato, Simone Mocellin, and Vincenzo Bronte.
520 $a There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. * Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication * Drs Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research * Summarizes the latest insights into how immune escape defines an essential trait of cancer * Includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression.
533 $a Electronic reproduction. $b Amsterdam : $c Elsevier Science & Technology, $d 2007. $n Mode of access: World Wide Web. $n System requirements: Web browser. $n Title from title screen (viewed on Aug. 2, 2007). $n Access may be restricted to users at subscribing institutions.
650 0 $a Cancer $x Immunotherapy. $3 406740
650 0 $a Antineoplastic agents $x Therapeutic use. $3 416363
650 0 $a Tumors $x Immunological aspects. $3 416364
650 1 2 $a Neoplasms $x therapy. $3 336986
650 2 2 $a Antineoplastic Agents $x therapeutic use. $3 343349
650 2 2 $a Immunotherapy $x methods. $3 416365
655 7 $a Electronic books. $2 local $3 336502
700 1 $a Prendergast, George C. $3 416361
700 1 $a Jaffee, Elizabeth M. $3 416362
710 2 $a ScienceDirect (Online service) $3 365609
776 1 $c Original $z 9780123725516 $z 0123725518 $w (DLC) 2007016864 $w (OCoLC)123692348
856 4 0 $3 ScienceDirect $u http://www.sciencedirect.com/science/book/9780123725516 $z An electronic book accessible through the World Wide Web; click for information
856 4 0 $3 Referex $u http://www.engineeringvillage.com/controller/servlet/OpenURL?genre=book&isbn=9780123725516 $z An electronic book accessible through the World Wide Web; click for information
856 4 1 $3 Table of contents only $u http://www.loc.gov/catdir/toc/ecip0716/2007016864.html
856 4 2 $3 Publisher description $u http://www.loc.gov/catdir/enhancements/fy0733/2007016864-d.html
994 $a C0 $b TEF